References
- Caron M. G., Lefkowitz R. J. Solubilization and characterization of beta-adrenergic receptor binding sites of frog erythrocytes. J.Biol.Chem. 1976; 251: 2374
- Bürgisser E. Model testing in radioligand/receptor interactions by Monte Carlo simulation. J.Receptor Res. 1983; 261
- Engel G., Hoyer D., Berthold R., Wagner H. (±)[125I]-cyanopindolol, a new ligand for beta-adrenoceptors: identification and quantitation of subclasses of beta-adrenoceptors in guinea pig. Naunyn-Schmiedeberg's. Arch. Pharmacol. 1981; 317: 277
- Cheng Y.-C., Prusoff W. H. Relationship between the inhibition constant (K) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem.Pharmacol. 1973; 22: 3099
- Duggleby R. G. A nonlinear regression program for small computer. Anal.Biochem. 1981; 110
- De Lean A., Munson P. J., Rodbard D. Simultanous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am.J.Physiol. 1978; 235((2))E97
- Evans E. A. Self-decomposition of radiochemicals. Review. Amersham International, AmershamUK, 16
- Munson P. J. Experimental artifacts and the analysis of ligand binding data: results of a computer simulation. J.Receptor Res. 1983; 249
- Bürgisser E., Hancock A. A., Lefkowitz R. J., De Lean A. Anomalous equilibrium binding properties of high-affinity racemic radioligands. Mol.Phamacol. 1981; 19: 205
- Bürgisser E., Lefkowitz R. J., De Lean A. Alternative explanation for the apparent “two-step” binding kinetics of high-affinity racematic radioligands. Mol.Pharmacol. 1981; 19: 509
- Doyle V. M., Bühler F. R., Bürgisser E. Inappropriate correction for radioactive decay in fully iodinated adrenergic radioligands. European J.Pharmacol. 1984; 99: 353